Genetic allergen modification in the development of novel approaches to specific immunotherapy

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical and Experimental Allergy

• Publication date

  2009-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2222.2009.03317.xPMID 19624521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural Self-Assembly of Allergen-S-Layer Fusion Proteins Is No Prerequisite for Reduced Allergenicity and T Cell Stimulatory Capacity

  2009cited by this paper
• The diagnosis of IgE‐mediated food allergy in childhood

  2009cited by this paper
• Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy

  2009cited by this paper
• Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll‐like receptors

  2008cited by this paper
• A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6

  2008cited by this paper
• Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

  2008cited by this paper
• Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives

  2008cited by this paper
• Targeting Fel d 1 to FcγRI induces a novel variation of the TH2 response in subjects with cat allergy

  2008cited by this paper
• Cellular and Humoral Mechanisms of Immune Tolerance in Immediate-Type Allergy Induced by Specific Immunotherapy

  2008cited by this paper
• Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering.

  2008cited by this paper
• "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling.

  2008cited by this paper
• The potential of allergen biochips.

  2008cited by this paper
• In vivo switch to IL-10–secreting T regulatory cells in high dose allergen exposure

  2008cited by this paper
• Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.

  2008cited by this paper
• EU Forum: The CREATE Project: development of certified reference materials for allergenic products and validation of methods for their quantification

  2008cited by this paper
• Carbohydrate‐based particles reduce allergic inflammation in a mouse model for cat allergy

  2008cited by this paper
• Targeting Fel d 1 to FcgammaRI induces a novel variation of the T(H)2 response in subjects with cat allergy.

  2008cited by this paper
• A Novel Approach to Specific Allergy Treatment: The Recombinant Allergen-S-Layer Fusion Protein rSbsC-Bet v 1 Matures Dendritic Cells That Prime Th0/Th1 and IL-10-Producing Regulatory T Cells1

  2007cited by this paper
• A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi‐sensitivities

  2007cited by this paper
• Allergic rhinitis and its impact on asthma update: allergen immunotherapy.

  2007cited by this paper
• Allergy multivaccines created by DNA shuffling of tree pollen allergens.

  2007cited by this paper
• Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation.

  2007cited by this paper
• A Recombinant Hypoallergenic Parvalbumin Mutant for Immunotherapy of IgE-Mediated Fish Allergy1

  2007cited by this paper
• A Hypoallergenic Vaccine Obtained by Tail-to-Head Restructuring of Timothy Grass Pollen Profilin, Phl p 12, for the Treatment of Cross-Sensitization to Profilin1

  2007cited by this paper
• Recombinant allergens for immunotherapy.

  2007cited by this paper
• Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses.

  2007cited by this paper
• Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis

  2007cited by this paper
• Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy.

  2007cited by this paper
• Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy

  2007cited by this paper
• Engineering allergens.

  2006cited by this paper
• Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines.

  2006cited by this paper
• IgE-Mediated Allergen Presentation and Blocking Antibodies: Regulation of T-Cell Activation in Allergy

  2006cited by this paper
• Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity.

  2006cited by this paper
• Mutational Analysis of Amino Acid Positions Crucial for IgE-Binding Epitopes of the Major Apple (Malus domestica) Allergen, Mal d 1

  2005cited by this paper
• A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy.

  2005cited by this paper
• Characterization of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not cross‐reactive with homologous pollen allergens

  2005cited by this paper
• A chimeric human-cat fusion protein blocks cat-induced allergy

  2005cited by this paper
• Monophosphoryl lipid A (MPL®) * promotes allergen‐induced immune deviation in favour of Th1 responses

  2005cited by this paper
• Allergen-specific immunotherapy with recombinant grass pollen allergens.

  2005cited by this paper
• Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice.

  2005cited by this paper
• Prevention of allergy by a recombinant multi‐allergen vaccine with reduced IgE binding and preserved T cell epitopes

  2005cited by this paper
• Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens.

  2005cited by this paper
• A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination.

  2005cited by this paper
• High Dose Allergen Stimulation of T Cells from House Dust Mite-Allergic Subjects Induces Expansion of IFN-γ+ T Cells, Apoptosis of CD4+IL-4+ T Cells and T Cell Anergy

  2004cited by this paper
• Vaccination with genetically engineered allergens prevents progression of allergic disease

  2004cited by this paper
• Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 71

  2004cited by this paper
• Allergen‐loaded biodegradable poly(d,l‐lactic‐co‐glycolic) acid nanoparticles down‐regulate an ongoing Th2 response in the BALB/c mouse model

  2004cited by this paper
• Improving diagnostic tests for food allergy with recombinant allergens.

  2004cited by this paper
• Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells

  2004cited by this paper
• A Novel Approach to Specific Allergy Treatment: The Recombinant Fusion Protein of a Bacterial Cell Surface (S-Layer) Protein and the Major Birch Pollen Allergen Bet v 1 (rSbsC-Bet v 1) Combines Reduced Allergenicity with Immunomodulating Capacity1

  2004cited by this paper
• Hypoallergenic Variants of the Major Latex Allergen Hev b 6.01 Retaining Human T Lymphocyte Reactivity1

  2004cited by this paper
• Induction of T ‘regulatory’ cells by standardized house dust mite immunotherapy: an increase in CD4+CD25+ interleukin‐10+ T cells expressing peripheral tissue trafficking markers

  2004cited by this paper
• Fc receptor biology.

  2003cited by this paper
• Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents.

  2003cited by this paper
• Induction of ‘blocking’ IgG antibodies during immunotherapy

  2003cited by this paper
• IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

  2003cited by this paper
• Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE‐binding capacity: candidates for grass pollen‐specific immunotherapy

  2002cited by this paper
• Ovalbumin fused with diphtheria toxin protects mice from ovalbumin induced anaphylactic shock.

  2001cited by this paper
• Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1

  2001cited by this paper
• Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity.

  2000cited by this paper
• T Cell Reactivity with Allergoids: Influence of the Type of APC

  2000cited by this paper
• Activating and inhibitory signaling in mast cells: new opportunities for therapeutic intervention?

  2000cited by this paper
• Recombinant allergens for immunotherapy

  2000cited by this paper
• Oligodeoxynucleotides containing CpG motifs induce IL‐12, IL‐18 and IFN‐γ production in cells from allergic individuals and inhibit IgE synthesis in vitro

  1999cited by this paper
• "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity.

  1999cited by this paper
• Long‐term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial

  1999cited by this paper
• Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy

  1998cited by this paper
• Preserved epitope‐specific T cell activation by recombinant Bet v 1‐MBP fusion proteins

  1998cited by this paper
• IgE versus IgG4 production can be differentially regulated by IL-10.

  1998cited by this paper
• Responses of human birch pollen allergen‐reactive T cells to chemically modified allergens (allergoids)

  1998cited by this paper
• An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production.

  1997cited by this paper
• Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

  1997cited by this paper
• Insect venom immunotherapy induces interleukin‐10 production and a Th2‐to‐Th1 shift, and changes surface marker expression in venom‐allergic subjects

  1997cited by this paper
• Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T‐cell clones specific for Phi p 1, a major grass pollen allergen

  1997cited by this paper
• Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy

  1996cited by this paper
• The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation.

  1995cited by this paper
• Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.

  1995cited by this paper
• Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type

  1995cited by this paper
• Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals

  1993cited by this paper
• Double-blind, placebo-controlled immunotherapy with a high-molecular-weight, formalinized allergoid in grass pollen allergy.

  1987cited by this paper
• The Subclass Nature and Clinical Significance of the IgG Antibody Response in Patients Undergoing Allergen‐Specific Immunotherapy

  1985cited by this paper
• Preparation and properties of ,allergoids, derived from native pollen allergens by mild formalin treatment.

  1971cited by this paper
• The FASEB Journal express article 10.1096/fj.01-1012fje. Published online June 21, 2002.

  year unknowncited by this paper

• New approaches to immunotherapy in house dust mite allergy

  2022cites this paper
• Isolation of nanobodies with potential to reduce patients' IgE binding to Bet v 1

  2021cites this paper
• Site-Directed Mutations of Calcium-Binding Sites Contribute to Reducing the Immunoreactivity of the EF-Hand Sarcoplasmic Calcium-Binding Protein in Scylla paramamosain.

  2020cites this paper
• Pollen used to produce allergen extracts.

  2017cites this paper
• Lipid Transfer Proteins As Components of the Plant Innate Immune System: Structure, Functions, and Applications

  2016cites this paper
• Considerations About Pollen Used for the Production of Allergen Extracts.

  2015cites this paper
• The dichotomy of pathogens and allergens in vaccination approaches

  2014cites this paper
• Hypoallergenic Mutants of the Timothy Grass Pollen Allergen Phl p 5 Generated by Proline Mutations

  2012cites this paper
• Birch Pollen-Related Food Allergy: An Excellent Disease Model to Understand the Relevance of Immunological Cross-Reactivity for Allergy

  2012cites this paper
• Immunogenicity of Phleum pratense depigmented allergoid vaccines: experimental study in rabbits.

  2012cites this paper
• Recombinant Allergens and Applications

  2012cites this paper
• A non-allergenic Ole e 1-like protein from birch pollen as a tool to design hypoallergenic vaccine candidates.

  2012cites this paper
• Seed-based oral vaccines as allergen-specific immunotherapies

  2011cites this paper
• Assessing Protein Immunogenicity with a Dendritic Cell Line-Derived Endolysosomal Degradome

  2011cites this paper
• Factors influencing the allergenicity and adjuvanticity of allergens.

  2011cites this paper
• Prevention and treatment of allergic asthma in pregnancy: from conventional drugs to new therapeutical approaches.

  2011cites this paper
• Epicutaneous allergen administration: is this the future of allergen‐specific immunotherapy?

  2011cites this paper
• Molecular cloning and expression in Pichia pastoris of a hypoallergenic antigen 5.

  2010cites this paper
• Developments in the field of allergy in 2009 through the eyes of Clinical and Experimental Allergy

  2010cites this paper